Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Metab Dispos ; 27(12): 1434-47, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10570025

ABSTRACT

The study objectives were to characterize the metabolism of nevirapine (NVP) in mouse, rat, rabbit, dog, monkey, and chimpanzee after oral administration of carbon-14-labeled or -unlabeled NVP. Liquid scintillation counting quantitated radioactivity and bile, plasma, urine, and feces were profiled by HPLC/UV diode array and radioactivity detection. Metabolite structures were confirmed by UV spectral and chromatographic retention time comparisons with synthetic metabolite standards, by beta-glucuronidase incubations, and in one case, by direct probe electron impact ionization/mass spectroscopy, chemical ionization/mass spectroscopy, and NMR. NVP was completely absorbed in both sexes of all species except male and female dogs. Parent compound accounted for <6% of total urinary radioactivity and <5.1% of total fecal radioactivity, except in dogs where 41 to 46% of the radioactivity was excreted as parent compound. The drug was extensively metabolized in both sexes of all animal species studied. Oxidation to hydroxylated metabolites occurred before glucuronide conjugation and excretion in urine and feces. Hydroxylated metabolites were 2-, 3-, 8-, and 12-hydroxynevirapine (2-, 3-, 8-, and 12-OHNVP). 4-carboxynevirapine, formed by secondary oxidation of 12-OHNVP, was a major urinary metabolite in all species except the female rat. Glucuronides of the hydroxylated metabolites were major or minor metabolites, depending on the species. Rat plasma profiles differed from urinary profiles with NVP and 12-OHNVP accounting for the majority of the total radioactivity. Dog plasma profiles, however, were similar to the urinary profiles with 12-OHNVP, its glucuronide conjugate, 4-carboxynevirapine, and 3-OHNVP glucuronide being the major metabolites. Overall, the same metabolites are formed in animals as are formed in humans.


Subject(s)
HIV Reverse Transcriptase/antagonists & inhibitors , Nevirapine/pharmacokinetics , Reverse Transcriptase Inhibitors/pharmacokinetics , Animals , Bile/metabolism , Biotransformation , Dogs , Feces/chemistry , Female , Glucuronidase/metabolism , Haplorhini , Hydrolysis , Magnetic Resonance Spectroscopy , Male , Mass Spectrometry , Metabolic Clearance Rate , Mice , Nevirapine/blood , Nevirapine/pharmacology , Nevirapine/urine , Pan troglodytes , Rabbits , Rats , Sex Factors , Species Specificity
2.
J Pharmacol Exp Ther ; 265(2): 483-9, 1993 May.
Article in English | MEDLINE | ID: mdl-8388452

ABSTRACT

BI-L-226, a 2,6-disubstituted 4-(2-arylethenyl)phenol, is a potent and selective 5-lipoxygenase inhibitor which shows excellent inhibition of antigen-induced leukotriene generation in the lung of cynomolgus monkeys by aerosol administration, although little activity has been observed by the p.o. route. The facile synthesis of the succinate ester BI-L-357, however, results in a prodrug which has p.o. activity between 10 to 30 mg/kg in an ex vivo whole blood model of leukotriene B4 generation in both squirrel and cynomolgus monkeys. In addition, the prodrug is effective in inhibiting pulmonary leukotriene C4 production in antigen-challenged cynomolgus monkeys in the same dose range. Plasma levels of the parent compound in the monkey after p.o. administration of 30 mg/kg are 25-fold higher than the IC50 needed for in vitro inhibition of leukotriene B4 in whole blood. Absolute bioavailability of the parent compound was 50%. The prodrug concept therefore extends the potential of this class of compounds to inflammation sites mediated by 5-lipoxygenase not readily treated by topical administration.


Subject(s)
Lipoxygenase Inhibitors/pharmacology , Phenols/pharmacology , Prodrugs/pharmacology , Thiophenes/pharmacology , Animals , Antigens , Biological Availability , Calcimycin/pharmacology , Female , Humans , Leukotriene B4/biosynthesis , Leukotriene B4/blood , Lipoxygenase Inhibitors/pharmacokinetics , Lung/metabolism , Macaca fascicularis , Male , Phenols/blood , Phenols/pharmacokinetics , Prodrugs/pharmacokinetics , SRS-A/antagonists & inhibitors , SRS-A/biosynthesis , Saimiri , Thiophenes/blood , Thiophenes/pharmacokinetics , Thromboxane B2/biosynthesis , Thromboxane B2/blood
3.
Drug Metab Dispos ; 10(3): 241-5, 1982.
Article in English | MEDLINE | ID: mdl-6125356

ABSTRACT

The disposition and metabolism of 14C-tiaramide HCl was examined in four healthy male volunteers, after administration of a 200-mg dose in solution. The mean cumulative recovery of administered radioactivity was 91.3 +/- 2.9% (mean +/- SD) in urine an 6.0 +/- 1.5% in feces. The elimination was rapid, with 83.9% of the radioactivity extracted in urine in the first 12 hr. The unchanged tiaramide serum concentration curve showed monoexponential elimination with a half-life of 1.3 hr. Peak serum levels, of 1.6-2.2 micrograms/ml were attained between 0.5 and 1.5 hr after dosing. Tiaramide was extensively metabolized, with less than 1% excreted unchanged. Urinary metabolites (80-95% of the dose) were identified by mass-spectral comparison to authentic standards. Biotransformation resulted in production of the N-acetic acid N-oxide, N-acetic acid, O-glucuronide, N-oxide, and desethanol metabolites of tiaramide.


Subject(s)
Anti-Inflammatory Agents/metabolism , Piperazines/metabolism , Adolescent , Anti-Inflammatory Agents/blood , Anti-Inflammatory Agents/urine , Benzothiazoles , Carbon Radioisotopes , Feces/analysis , Humans , Isotope Labeling , Male , Piperazines/blood , Piperazines/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...